Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Gorello, G. Cazzaniga, F. Alberti, M. Dell'oro, E. Gottardi, G. Specchia, G. Roti, R. Rosati, M. Martelli, D. Diverio, F. Coco, A. Biondi, G. Saglio, C. Mecucci, B. Falini (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutationsLeukemia, 20
P. Loo, Silje Nordgard, O. Lingjærde, H. Russnes, I. Rye, Wei Sun, V. Weigman, P. Marynen, A. Zetterberg, B. Naume, C. Perou, A. Børresen-Dale, V. Kristensen (2010)
Allele-specific copy number analysis of tumorsProceedings of the National Academy of Sciences, 107
A. Biankin, N. Waddell, K. Kassahn, M. Gingras, L. Muthuswamy, A. Johns, David Miller, P. Wilson, A. Patch, Jianmin Wu, D. Chang, M. Cowley, B. Gardiner, Sarah Song, Ivon Harliwong, S. Idrisoglu, C. Nourse, Ehsan Nourbakhsh, Suzanne Manning, Shivangi Wani, M. Gongora, M. Pajic, C. Scarlett, A. Gill, Andreia Pinho, I. Rooman, M. Anderson, O. Holmes, C. Leonard, Darrin Taylor, S. Wood, Qinying Xu, K. Nones, J. Fink, Angelika Christ, T. Bruxner, N. Cloonan, G. Kolle, F. Newell, M. Pinese, R. Mead, J. Humphris, W. Kaplan, Marc Jones, E. Colvin, A. Nagrial, Emily Humphrey, A. Chou, V. Chin, L. Chantrill, A. Mawson, J. Samra, J. Kench, Jessica Lovell, R. Daly, N. Merrett, C. Toon, K. Epari, N. Nguyen, A. Barbour, N. Zeps, N. Kakkar, Fengmei Zhao, Y. Wu, Min Wang, D. Muzny, W. Fisher, F. Brunicardi, S. Hodges, J. Reid, J. Drummond, K. Chang, Yi Han, L. Lewis, H. Dinh, C. Buhay, T. Beck, Lee Timms, M. Sam, K. Begley, Andrew Brown, D. Pai, A. Panchal, Nicholas Buchner, R. Borja, R. Denroche, C. Yung, S. Serra, N. Onetto, D. Mukhopadhyay, M. Tsao, P. Shaw, G. Petersen, S. Gallinger, R. Hruban, A. Maitra, C. Iacobuzio-Donahue, R. Schulick, elliot fishman, R. Morgan, R. Lawlor, P. Capelli, V. Corbo, M. Scardoni, G. Tortora, M. Tempero, K. Mann, N. Jenkins, P. Pérez-Mancera, D. Adams, D. Largaespada, L. Wessels, A. Rust, Lincoln Stein, D. Tuveson, N. Copeland, E. Musgrove, A. Scarpa, J. Eshleman, T. Hudson, R. Sutherland, D. Wheeler, J. Pearson, J. McPherson, R. Gibbs, S. Grimmond (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 491
M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R. Shapiro, R. Berman, A. Pavlick, F. Darvishian, P. Christos, M. Mazumdar, I. Osman, D. Polsky (2012)
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic MelanomaPLoS ONE, 7
Xiao-fei Zhao, Anyou Wang, Vonn Walter, Nirali Patel, David Eberhard, M. Hayward, Ashley Salazar, Heejoon Jo, Matthew Soloway, M. Wilkerson, Joel Parker, Xiaoying Yin, Guosheng Zhang, Marni Siegel, Gary Rosson, H. Earp, Norman Sharpless, M. Gulley, K. Weck, D. Hayes, S. Moschos (2015)
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLCPLoS ONE, 10
J. Dudley, L. Tseng, L. Rooper, Marco Harris, Lisa Haley, Guoli Chen, C. Gocke, J. Eshleman, Ming-Tseh Lin (2015)
Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.Archives of pathology & laboratory medicine, 139 2
M. Wilkerson, Xiaoying Yin, Vonn Walter, N. Zhao, Christopher Cabanski, M. Hayward, C. Miller, M. Socinski, A. Parsons, L. Thorne, B. Haithcock, N. Veeramachaneni, W. Funkhouser, S. Randell, P. Bernard, C. Perou, D. Hayes (2012)
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and MethylationPLoS ONE, 7
A. Taylor-Weiner, Travis Zack, E. O’Donnell, Jennifer Guerriero, Brandon Bernard, A. Reddy, G. Han, S. AlDubayan, Ali Amin-Mansour, S. Schumacher, K. Litchfield, C. Turnbull, S. Gabriel, R. Beroukhim, G. Getz, S. Carter, M. Hirsch, A. Letai, C. Sweeney, E. Allen (2016)
Genomic evolution and chemoresistance in germ-cell tumoursNature, 540
A. Smits, J. Kummer, P. Bruin, Mijke Bol, J. Tweel, K. Seldenrijk, S. Willems, G. Offerhaus, R. Weger, P. Diest, A. Vink (2014)
The estimation of tumor cell percentage for molecular testing by pathologists is not accurateModern Pathology, 27
Hollis Viray, Kevin Li, T. Long, P. Vasalos, J. Bridge, L. Jennings, K. Halling, M. Hameed, D. Rimm (2013)
A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.Archives of pathology & laboratory medicine, 137 11
C. Davidson, E. Zeringer, K. Champion, Marie-Pierre Gauthier, Fawn Wang, J. Boonyaratanakornkit, Julie Jones, E. Schreiber (2012)
Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection.BioTechniques, 53 3
E. Papaemmanuil, M. Gerstung, L. Bullinger, V. Gaidzik, P. Paschka, Nicola Roberts, N. Potter, M. Heuser, F. Thol, N. Bolli, G. Gundem, P. Loo, I. Martincorena, P. Ganly, L. Mudie, Stuart Mclaren, S. O'meara, K. Raine, David Jones, J. Teague, A. Butler, M. Greaves, A. Ganser, K. Döhner, R. Schlenk, H. Döhner, P. Campbell (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia.The New England journal of medicine, 374 23
N. Andor, Julie Harness, S. Müller, H. Mewes, C. Petritsch (2013)
EXPANDS: expanding ploidy and allele frequency on nested subpopulationsBioinformatics, 30
P. Muller, K. Vousden (2013)
p53 mutations in cancerNature Cell Biology, 15
M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, Sharmin Begum, N. McDonald, A. Butler, David Jones, K. Raine, Calli Latimer, Claudio Santos, M. Nohadani, A. Eklund, B. Spencer‐Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. Futreal, C. Swanton (2012)
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.The New England journal of medicine, 366 10
J. Grilley-Olson, D. Hayes, D. Moore, K. Leslie, M. Wilkerson, B. Qaqish, M. Hayward, Christopher Cabanski, Xiaoying Yin, M. Socinski, T. Stinchcombe, L. Thorne, T. Allen, P. Banks, M. Beasley, A. Borczuk, P. Cagle, R. Christensen, T. Colby, G. Deblois, G. Elmberger, P. Graziano, C. Hart, K. Jones, D. Maia, C. Miller, K. Nance, W. Travis, W. Funkhouser (2013)
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.Archives of pathology & laboratory medicine, 137 1
X. Su, Li Zhang, Jianping Zhang, F. Meric-Bernstam, J. Weinstein (2012)
PurityEst: estimating purity of human tumor samples using next-generation sequencing dataBioinformatics, 28 17
S. Carter, K. Cibulskis, E. Helman, A. McKenna, Hui Shen, Travis Zack, P. Laird, R. Onofrio, W. Winckler, B. Weir, R. Beroukhim, D. Pellman, D. Levine, E. Lander, M. Meyerson, G. Getz (2012)
Absolute quantification of somatic DNA alterations in human cancerNature biotechnology, 30
Layla Oesper, Gryte Satas, Benjamin Raphael (2014)
Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing dataBioinformatics, 30 24
Coleman Lindsley, W. Saber, B. Mar, R. Redd, Tao Wang, M. Haagenson, Peter Grauman, Zhen-Huan Hu, S. Spellman, Stephanie Lee, M. Verneris, K. Hsu, K. Fleischhauer, C. Cutler, J. Antin, D. Neuberg, B. Ebert (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell TransplantationThe New England Journal of Medicine, 376
(2013)
DNA sequencing costs: data from the NHGRI Genome sequencing program (GSP)
N. Larson, B. Fridley (2013)
PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing dataBioinformatics, 29 15
The Network (2013)
COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMANature, 499
Neoplastic cellularity contributes to the analytic sensitivity of most present technologies for mutation detection, such that they underperform when stroma and inflammatory cells dilute a cancer specimen’s variant fraction. Thus, tumor purity assessment by light microscopy is used to determine sample adequacy before sequencing and to interpret the significance of negative results and mutant allele fraction afterwards. However, pathologist estimates of tumor purity are imprecise and have limited reproducibility. With the advent of massively parallel sequencing, large amounts of molecular data can be analyzed by computational purity algorithms. We retrospectively compared tumor purity of 3 computational algorithms with neoplastic cellularity using hematoxylin and eosin light microscopy to determine which was best for clinical evaluation of molecular profiling. Data were analyzed from 881 cancer patients from a clinical trial cohort, LCCC1108 (UNCseq), whose tumors had targeted massively parallel sequencing. Concordance among algorithms was poor, and the specimens analyzed had high rates of algorithm failure partially due to variable tumor purity. Computational tumor purity estimates did not add value beyond the pathologist’s estimate of neoplastic cellularity microscopy. To improve present methods, we propose a semiquantitative, clinically applicable strategy based on mutant allele fraction and copy number changes present within a given specimen, which when combined with the morphologic tumor purity estimate, guide the interpretation of next-generation sequencing results in cancer patients.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Nov 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.